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Background: The number of potential regimens of drug treat-
ment for TB is vast, meaning that evaluating each new treatment
against a control in separate two-arm trials requires a huge amount
of resources. There is, therefore, a need for innovative trial designs
that can evaluate drug regimens simultaneously.
Methods & Materials: TRUNCATE-TB (two-month regimens
using novel combinations to augment treatment effectiveness for
drug-sensitive tuberculosis) is a randomised, open-label, multi-
arm, multi-stage (MAMS), parallel group strategy trial. The MAMS
design has been applied successfuly in a trial of multiple regi-
mens for prostate cancer, and more recently in a TB trial. In the
MAMS design, the trial starts with multiple arms, and, as it pro-
gresses, recruitment to those arms that do not show sufﬁcient
promise on an early interim outcome measure are discontinued,
whilst recruitment to the control arm and remaining promising
novel boosted arms continues until sufﬁcient numbers of patients
have been enrolled to assess the outcome on the deﬁned primary
outcome. Recommendations about stoppingor continuing armsare
made by an Independent Data Monitoring Committee on the basis
of safety and efﬁcacy data.
Results: Up to 1080 adult patients with pulmonary TB (diag-
nosed using sputum GeneXpert) will be randomised at equal
probability to receive 6-months standard treatment as a control, or
to one of a number of boosted regimens (these regimens are combi-
nations of standard drugswith new or repurposed drugs including:
high-dose rifampicin, linezolid, clofazimine, bedaquiline, dela-
manid, rifapentine or levoﬂoxacin.
Conclusion: The primary aim of the trial is to determine
whether a strategy of treating drug-sensitive TB for 2 months
with one of a number of novel combination regimens and re-
treating relapse with a 6-month course of standard treatment
will be non-inferior to the standard WHO-recommended 6-month
treatment/8-month re-treatment approach in terms of TB sputum
culture status at 2 years after randomisation. The secondary aims
are to assess the possible advantages of the TRUNCATE-TB man-
agement strategy compared to the standard management strategy
from the patient perspective (including acceptability, quality of
life and clinical adverse events) and the programme perspective
(including treatment adherence, default, new drug resistance and
community transmission) as well as cost-effectiveness.
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Identiﬁcation of new efﬂux pump proteins from
multidrug resistant Mycobacterium
tuberculosis and screening for peptide based
efﬂux pump inhibitors
K. Parthasarathy1,∗, A. Sivaraj2, R. Sundar2
1 Sathyabama University, chennai, tamilnadu, India
2 Sathyabama University, Chennai, India
Background: Tuberculosis (TB) continues to be one of the
main causes of morbidity and mortality worldwide. The alarming
increase in the rate of HIV-related TB, pediatric TB, latent TB, Multi
DrugResistant (MDR)andExtensivelyDrugResistant (XDR)TBpose
serious problem around the world. The treatment for tuberculosis
requires very long duration with combination of antibiotics (6-8
months for new cases and 18-24 months for MDR TB). Two mech-
anisms are thought to be involved in the natural drug resistance
of mycobacteria: the mycobacterial cell wall permeability barrier
and active multidrug efﬂux pumps. Genes encoding drug efﬂux
transportershavebeen isolated fromseveralmycobacterial species.
These proteins transport tetracycline, ﬂuoroquinolones, aminogly-
cosides and other compounds. Recent reports have suggested that
efﬂux pumps may also be involved in transporting isoniazid, one of
themain drugs used to treat tuberculosis. Inmost bacterial species,
efﬂux pump inhibitors (EPI) can reduce resistance levels both in
wild-type strains and in those with acquired target mutations.
Methods & Materials: Identiﬁcation of MTB efﬂux pump genes
MDR-MTB identiﬁcation
Gene Cloning from MDR-MTB, Nucleotide sequencing and
Mutation analysis
Isolation and indetiﬁcation of Peptide inhibitors fromLactic acid
bacteria (LAB)
Mycobacterium tuberculosis inhibitor assay
Luciferase assay
Results: In this study we have identiﬁed a list of genes which
might function as potential drug efﬂux pumps from the MDR-MTB
clinical isolates. These genes were identiﬁed based on sequence
analysis of the corresponding efﬂux genes with that of the MTB
strain H37Rv. Crucial mutations in these genes might have an
important role in the drug efﬂux inMDR-MTB. The identiﬁed genes
were expressed in drug resistant E.coli. The isolated peptides from
LAB and known drug efﬂux pump inhibitors in combination with
RIF and INH were tested in E.coli (Efﬂux genes) and MDR-MTB.
Conclusion: Nucleotide comparison studies with the H37Rv
strain we have identiﬁed potential candidate genes related to drug
